JP2019506412A5 - - Google Patents

Download PDF

Info

Publication number
JP2019506412A5
JP2019506412A5 JP2018541386A JP2018541386A JP2019506412A5 JP 2019506412 A5 JP2019506412 A5 JP 2019506412A5 JP 2018541386 A JP2018541386 A JP 2018541386A JP 2018541386 A JP2018541386 A JP 2018541386A JP 2019506412 A5 JP2019506412 A5 JP 2019506412A5
Authority
JP
Japan
Prior art keywords
seq
antibody
lam
antigen
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018541386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016058 external-priority patent/WO2017139153A1/en
Publication of JP2019506412A publication Critical patent/JP2019506412A/ja
Publication of JP2019506412A5 publication Critical patent/JP2019506412A5/ja
Priority to JP2021063301A priority Critical patent/JP7316685B2/ja
Priority to JP2023031004A priority patent/JP2023075196A/ja
Priority to JP2024137825A priority patent/JP7813481B2/ja
Pending legal-status Critical Current

Links

JP2018541386A 2016-02-10 2017-02-01 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体 Pending JP2019506412A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021063301A JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2023031004A JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2024137825A JP7813481B2 (ja) 2016-02-10 2024-08-19 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
US62/293,406 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021063301A Division JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2019506412A JP2019506412A (ja) 2019-03-07
JP2019506412A5 true JP2019506412A5 (enExample) 2020-03-12

Family

ID=59563993

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541386A Pending JP2019506412A (ja) 2016-02-10 2017-02-01 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体
JP2021063301A Active JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2023031004A Pending JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2024137825A Active JP7813481B2 (ja) 2016-02-10 2024-08-19 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021063301A Active JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2023031004A Pending JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP2024137825A Active JP7813481B2 (ja) 2016-02-10 2024-08-19 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体

Country Status (10)

Country Link
US (4) US10729771B2 (enExample)
EP (2) EP4299072A3 (enExample)
JP (4) JP2019506412A (enExample)
CN (2) CN110092830B (enExample)
AU (2) AU2017218415B2 (enExample)
CA (1) CA3013904C (enExample)
ES (1) ES2970828T3 (enExample)
RU (1) RU2732502C2 (enExample)
WO (1) WO2017139153A1 (enExample)
ZA (3) ZA201805990B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019506412A (ja) 2016-02-10 2019-03-07 ラトガース, ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体
US10830760B2 (en) * 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
US20210025887A1 (en) * 2018-03-29 2021-01-28 Foundation Of Innovative New Diagnostics Antibody or antibody combination and method using same for detection of an antigen related to mycobacterium in a urine sample of a subject
US20210302424A1 (en) 2018-07-19 2021-09-30 Rutgers, The State University Of New Jersey Methods for dual detection and differentiation of infection by mycobacterium tuberculosis complex and nontuberculous mycobacteria
CN112639472A (zh) 2018-08-31 2021-04-09 富士胶片株式会社 免疫层析试剂盒及结核菌的检测方法
JP7192146B2 (ja) 2019-09-30 2022-12-19 富士フイルム株式会社 免疫検査方法及び濃縮用治具
WO2021065144A1 (ja) 2019-09-30 2021-04-08 富士フイルム株式会社 イムノクロマトグラフィー
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
EP4099017A4 (en) 2020-01-31 2023-02-15 FUJIFILM Corporation IMMUNOLOGICAL TEST PROCEDURE
EP4099016A4 (en) 2020-01-31 2023-02-15 FUJIFILM Corporation IMMUNOCHROMATOGRAPHY
WO2021152966A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 イムノクロマトグラフィー
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
EP4178610A4 (en) * 2020-07-07 2024-08-28 The Regents Of The University Of California METHODS FOR DETECTION OF ANTIGENS FROM DIRECT CLINICAL SAMPLES
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
CN116171378B (zh) 2020-09-11 2026-01-13 富士胶片株式会社 被检体液的浓缩方法、及被检体液的检查方法
WO2022054516A1 (ja) 2020-09-11 2022-03-17 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
JP7425883B2 (ja) 2020-09-11 2024-01-31 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
US20240101650A1 (en) * 2020-12-15 2024-03-28 Albert Einstein College Of Medicine High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) * 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
WO2002085335A1 (en) 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
WO2006012413A1 (en) * 2004-07-20 2006-02-02 Chemogen, Inc. Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
CA2737667A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Targeted binding agents directed to cd105 and uses thereof
JP5858283B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
SG192047A1 (en) * 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
EP2821415B1 (en) * 2012-02-29 2021-03-31 Otsuka Pharmaceutical Co., Ltd. Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
JP2019506412A (ja) 2016-02-10 2019-03-07 ラトガース, ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗−LAMおよび抗−PIM6/LAMモノクローナル抗体

Similar Documents

Publication Publication Date Title
JP2021105034A5 (enExample)
RU2018131622A (ru) Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
JP2019523651A5 (enExample)
JP2021502984A5 (enExample)
RU2015155552A (ru) Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
JP2013506428A5 (enExample)
JP2017524725A5 (enExample)
JP2009517057A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2016505634A5 (enExample)
JP2012530906A5 (enExample)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2018522888A5 (enExample)
JP2013538057A5 (enExample)
EP2301968A3 (en) Humanized monoclonal antibody HPAM4
JP2014526898A5 (enExample)
JP2020524510A5 (enExample)
RU2018137110A (ru) Антитела против psma и их применение
JP2020516603A5 (enExample)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2015527368A5 (enExample)
JP2016516400A5 (enExample)
JP2016501877A5 (enExample)
JP2015529202A5 (enExample)
JP2018526642A5 (enExample)